Yan L.,Peoples Hospital of Jinghong |
Wang Q.-W.,Peoples Hospital of Jinghong
Chinese Journal of Cancer Prevention and Treatment | Year: 2013
OBJECTIVE: To investigate the distribution of let-7 target gene KRAS-binding domain rs712 polymorphism in patients with glioma and healthy controls and its correlation with clinical features of glioma. METHODS: The KRAS rs712 polymorphism was genotyped in 153 patients with glioma and 204 healthy controls using polymerase chain reaction-restriction fragment length polymorphism method. RESULTS: The frequencies of GG, GT, and TT genotypes of rs712 were 67.2%, 29.9% and 2.9% in controls, 54.2%, 36.6% and 9.2% in patients with glioma, respectively. The TT and GT/TT genotypes were associated with increased risks of glioma compared with the GG genotype (TT vs GG: χ2=7.93, OR=3.85, 95%CI:1.43-10.41, P=0.005; GT/TT vs GG:χ2=6.16, OR=1.73, 95%CI:1.12-2.66, P=0.013, respectively). The frequencies of G and T alleles of rs712 were 82.1% and 17.9% in controls; and 72.5% and 27.5% in patients with glioma, respectively. Similarly, the T allele was correlated to a significantly increased risk of glioma compared with the G allele (χ2 =9.31, OR=1.74, 95%CI: 1.22-2.48, P=0.002). The frequencies of GT/TT genotypes and T allele in the III-IV grade glioma patients were significantly higher than those in patients with stage I-II (GT/TT vs GG:χ2=4.40, OR=1.99, 95%CI:1.04-3.81, P=0.036; T vs G:χ2=5.51, OR=1.83, 95%CI:1.10-3.04, P=0.019, respectively). CONCLUSION: KRAS rs712 allele polymorphism may be one of the susceptibility factors for glioma.
Hou S.-P.,Shanghai JiaoTong University |
Chen O.-J.,Shanghai Institute of Planned Parenthood Research |
Huang L.-H.,Peoples Hospital of Jinghong |
Cheng L.-N.,Shanghai Institute of Planned Parenthood Research |
Teng Y.-C.,Shanghai JiaoTong University
European Journal of Obstetrics Gynecology and Reproductive Biology | Year: 2013
In China, most women with intrauterine devices (IUDs) ask to have them removed following the menopause. As the cervix is stenotic after the menopause and most IUDs do not have a thread attached, various medical methods are used for cervical ripening prior to IUD removal. A systematic review of the relevant literature was conducted to compare different medical methods for cervical priming with no treatment, or with other methods, prior to IUD removal in postmenopausal women. Multiple electronic databases including the Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, the WHO Reproductive Health Library (2011) and the Chinese Biomedical Literature Database were searched systematically. Reference lists of articles published in English or Chinese between 1980 and 2011 were searched. All randomized controlled trials (RCTs) on IUD removal following the menopause using medical agents compared with no treatment, or with other treatments, were included. Outcomes were the ease of IUD removal, need for forced cervical dilatation, cervical width, procedure time, severe pain and any side-effects. Data were processed using RevMan 5 software. Thirty original RCTs were eligible for inclusion. Most medical agents such as oestrogens, mifepristone, misoprostol and methyl carboprost were highly effective for facilitating IUD removal, and reduced the need for further dilatation during the procedure. In particular, treatment with mifepristone or misoprostol prior to IUD removal was found to increase the width of the cervical canal and reduce the procedure time. Mifepristone was more effective than vaginal misoprostol for cervical dilatation, but it showed similar effectiveness to misoprostol and nilestriol in terms of the ease of IUD removal. Sublingual misoprostol was superior to oral misoprostol for facilitating IUD removal. A dose of misoprostol as low as 200 μg was effective for cervical priming. For vaginal and oral misoprostol, the optimum times of application were 2-3 h and 1 day prior to the procedure, respectively. All the prophylactic medical methods were able to alleviate pain during IUD removal, and vaginal misoprostol was more effective than nilestriol. Uterine injury was more common with no treatment and with nilestriol. Gastrointestinal side-effects such as nausea and diarrhoea were common with oral misoprostol and vaginal misoprostol, respectively. Therefore, mifepristone or sublingual misoprostol should be the medical treatments of choice. Oestrogen regimens might be alternatives when mifepristone or misoprostol are contraindicated, and there is a need for further study on combined regimens for cervical priming. © 2013 Elsevier Ireland Ltd. All rights reserved.
PubMed | Peoples Hospital of Jinghong and Peking Union Medical College
Type: | Journal: Scientific reports | Year: 2016
A total of 1067 serum samples were collected from febrile patients in Xishuangbanna, Yunnan, 2015. Of these, 852 cases were confirmed to be dengue NS1-positive. 76 structural protein genes were sequenced through RT-PCR based on the viral RNAs extracted from serum samples. Phylogenetic analysis revealed that all strains were classified as cosmopolitan genotype of DENV-2. After comparing with the DENV-2SS, 173 base substitutions were found in 76 sequences, resulting in 43 nonsynonymous mutations, of which 22 mutations existed among all samples. According to secondary structure prediction, 8 new possible nucelotide/protein binding sites were found and another 4 sites were lost among the 775 amino acids of DENV structural proteins as compared with DENV-2SS. Meanwhile, 6 distinct amino acid changes were found in the helix and strand regions, and the distribution of the exposed and buried regions was slightly altered. The results indicated that the epidemic dengue strains of Xishuangbanna in 2015 are most similar to the Indian strain in 2001 and the Sri Lankan strain in 2004. Moreover, it also show a very strong similarity to the epidemic strains of Fujian province in 1999 and 2010, which show that there is an internal recycling epidemic trend of DENV in China.
PubMed | Fujian Medical University, Peoples Hospital of Jinghong and Jiangsu University
Type: Journal Article | Journal: International journal of clinical and experimental medicine | Year: 2016
Several studies have focused on the correlation between the programmed death-1 (PD-1) rs2227981 C > T polymorphism and the risk of cancer; however, the results of such studies remain conflicting. To address this gap, we performed this meta-analysis to identify the potential association. Search strategies were performed in PubMed and EMBASE using appropriate terms. In total, 2,977 cancer cases and 2,642 controls from seven publications were recruited in our study. According to the seven eligible publications, the odds ratios (ORs) and 95% confidence intervals (CIs) on the risk of cancer for the TT vs. CC and TT vs. CT+CC genotypes were 0.67 and 0.50-0.91 and 0.65 and 0.47-0.90, respectively. In a subgroup analysis by cancer type, PD-1 rs2227981 C > T polymorphism was associated with a significantly decreased risk of breast cancer (OR, 0.82; 95% CI, 0.71-0.95; P = 0.009 for T vs. C and OR, 0.76; 95% CI, 0.63-0.92; P = 0.005 for TT+CT vs. CC) and of other cancer (OR, 0.58; 95% CI, 0.36-0.92; P = 0.004 for TT vs. CT+CC). In a subgroup analysis by ethnicity, a significant decreased cancer risk was identified among Asians (OR, 0.74; 95% CI, 0.63-0.86; P < 0.001 for T vs. C and OR, 0.71; 95% CI, 0.59-0.87; P = 0.001 for TT+CT vs. CC) and among Caucasians (OR, 0.66; 95% CI, 0.44-0.99; P = 0.047 for TT vs. CT+CC). These findings highlight the fact that the T allele of PD-1 rs2227981 C > T polymorphism modestly decreases the susceptibility of cancer. Nevertheless, further large and well-designed studies are needed to enrich the evidence of this association.
PubMed | Fujian Medical University, Peoples Hospital of Jinghong, Fujian Provincial Cancer Hospital and Jiangsu University
Type: Journal Article | Journal: Scandinavian journal of immunology | Year: 2016
To assess the potential effects of Cytotoxic T-lymphocyte antigen 4 (CTLA4) gene polymorphisms on susceptibility to gastric cardia adenocarcinoma (GCA), we genotyped four polymorphisms (rs733618 A>G, rs16840252 C>T, rs231775 G>A and rs3087243 G>A) in CTLA4 and calculated odds ratios (ORs) with the corresponding 95% confidence intervals (95% CIs) for the genotype and allele distributions between GCA cases and controls. The CTLA4 genotypes were determined by the polymerase chain reaction-ligase detection reaction (PCR-LDR) analysis in 330 GCA patients and 608 unrelated cancer-free controls. In this case-control study, there was no significant difference in the genotype and allele distributions of four CTLA4 polymorphisms between GCA patients and controls. However, haplotype association analysis indicated that compared with CTLA4 Grs733618 Crs16840252 Grs231775 Crs3087243 , CTLA4 Grs733618 Crs16840252 Ars231775 Grs3087243 and Ars733618 Crs16840252 Grs231775 Ars3087243 haplotypes conferred increased risks of GCA (OR = 6.46, 95% CI = 1.33-31.28; P = 0.012; both); however, CTLA4 Ars733618 Crs16840252 Ars231775 Grs3087243 and Ars733618 Trs16840252 Grs231775 Grs3087243 haplotypes conferred decreased risks of GCA (P = 0.001 and P = 0.011, respectively). These results highlight that the rare CTLA4 haplotypes may affect the development of GCA in the Chinese population.
PubMed | Peoples Hospital of Jinghong, Central South University, Guangxi University and Jiangxi Provincial Cancer Hospital
Type: Journal Article | Journal: Experimental and therapeutic medicine | Year: 2016
Doxorubicin (DOX) is an effective anthracycline anti-tumor antibiotic. Because of its cardiotoxicity, the clinical application of DOX is limited. Paeoniflorin (PEF), a monoterpene glucoside extracted from the dry root of Paeonia, is reported to exert multiple beneficial effects on the cardiovascular system. The present study was designed to explore the protective effect of PEF against DOX-induced cardiomyocyte apoptosis and the underlying mechanism. In cultured H9c2 cells, PEF (100 mol/l) was added for 2 h prior to exposure to DOX (5 mol/l) for 24 h. Cell viability, creatine kinase activity, cardiomyocyte apoptosis, intracellular reactive oxygen species (ROS) levels, and the expression of microRNA-1 (miR-1) and B-cell lymphoma 2 (Bcl-2) were measured following treatment with PEF and/or DOX. The results showed that treatment with DOX notably induced cardiomyocyte apoptosis, concomitantly with enhanced ROS generation, upregulated miR-1 expression and downregulated Bcl-2 expression. These effects of DOX were significantly inhibited by pretreatment of the cells with PEF. These results suggest that the inhibitory effect of PEF on DOX-induced cardiomyocyte apoptosis may be associated with downregulation of miR-1 expression via a reduction in ROS generation.
Lin Z.-H.,Peoples Hospital of Jinghong
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2010
OBJECTIVE: To compare the safety, efficacy, incidence of complication and comfort degree of various hemostasis device used in femoral artery hemostasis following cardiovascular intervention. METHODS: A computer-based online search of VIP was performed for articles related to hemostasis device in cardiovascular intervention published between January 1998 and October 2009 with the key words "hemostasis device, coronary angiography, percutaneous coronary intervention". Inclusion criteria: (1) articles with close correlation with the content; (2) articles in the same filed published recently or in authoritative journals; (3) old or repetitive articles. The data were primarily reviewed and the references of each articles were examined. RESULTS: A total of 72 articles were collected. After screening the titles and abstracts, 20 articles not related with the content, and 32 repetitive studies were excluded, and 20 were included. Currently, the hemostasis methods for femoral artery puncture site following coronary intervention included manually compressive hemostasis, mechanical compressive hemostasis and hemostasis device. Traditional manual or mechanical compression requires long periods of compression and braking, which increases risks for complications, and impairs the patients and prolongs the hospital stay. The novel suture or occlusion device for puncture site used in clinic, such as Angio-Seal or Perclose, significantly reduces bed lying and hospital stay of the patients, and attenuates peripheral vascular damages. CONCLUSION: For clinical physicians, it is necessary to consider the safety and efficacy, as well as the ratio of cost and quality for selection of hemostasis device, so that the patients can satisfy the clinical effects.
Fan S.-C.,Peoples Hospital of Jinghong |
Wang H.-J.,Peoples Hospital of Jinghong
Chinese Journal of Contemporary Neurology and Neurosurgery | Year: 2015
Retrospective analysis was performed on 30 patients of skull defect who underwent surgical repair. Intraoperative and postoperative curative effect was evaluated on those patients, and the results showed that the incidence rate of intraoperative dura mater defect (P = 0.001), early postoperative complications [new epilepsy (P = 0.035) and effusion (P = 0.021)] and late postoperative complications [foreign body sensation (P = 0.035) and dizziness and headache (P = 0.050)] in long-term skull defect group were all higher than those in control group. In conclusion, surgical repair of long-term skull defect incurring high risk and various complications will not be an ideal management. Therefore, early surgical treatment for skull defect is suggested. Copyright © 2015 by the Editorial Board of Chinese Journal of Contemporary Neurology and Neurosurgery.
Lin Z.,Peoples Hospital of Jinghong
Applied Mechanics and Materials | Year: 2012
OBJECTIVE: To investigate the clinical efficacy and safety of low-energy direct current defibrillation combined with intravenous application of β-receptor blocker in the treatment of ventricular tachycardia storm (VTS). METHODS: A total of 59 patients with VTS were randomly divided into two groups. In the control group (n = 31), intravenous administration of Lidocaine or Amiodarone and routine electrical defibrillation were performed. In the esmolol group (n = 28), intravenous administration of esmolol and low-energy electrical defibrillation were performed in addition to the same drug treatment as the control group. RESULTS: The success rate of terminating recurrent ventricular tachycardia or ventricular fibrillation was significantly higher in the esmolol group than in the control group (89.71% vs. 39.89%, P < 0.05). The necessary discharge times and average discharge energy to terminate ventricular tachycardia or ventricular fibrillation were significantly decreased in the esmolol group compared with control (5.69 ± 1.34 times vs. 8.63 ± 3.79 times, 95.32 ± 13.21J vs. 185.39 ± 25.63J, both P < 0.05). There was no significant difference in the incidence of hypotension (45.16% vs. 39.29%), sinus bradycardia (3.23% vs. 3.57%), and junctional/ventricular escape (38.71% vs. 39.29%) between the esmolol and control groups (all P > 0.05). The mortality was significantly lower in the esmolol group than in the control group (21.43%, 6/28 vs. 77.42%, 24/31, P < 0.01). CONCLUSION: Compared with conventional treatment, intravenous administration of a β-receptor blocker combined with low-energy electrical defibrillation could be a safe and effective therapy to treat VTS.
PubMed | University of Sichuan, Peoples Hospital of Jinghong and Sichuan Industrial Institute of Antibiotics
Type: Journal Article | Journal: Biomedical chromatography : BMC | Year: 2016
Nitrofibriate, a new compound of hypolipidemic, is modified based on fenofibrate. Both of them are used for prevention and treatment of cardiovascular diseases. In this study, an accurate and sensitive analytical method of reversed-phase high-performance liquid chromatography was developed to determine fenofibric acid, which is an active metabolite of both nitrofibriate and fenofibrate in rat plasma. This method was validated and successfully applied to pharmacokinetic study of nitrofibriate and fenofibrate after oral administration. The results suggested that the pharmacokinetic behavior of nitrofibriate followed a nonlinear process, while fenofibrate was linear, demonstrating that the two drugs were different in pharmacokinetic behaviors. Moreover, the effect of fenofibrate and nitrofibriate on releasing NO in rat serum was explored. This study showed that nitrofibriate, as a nitric oxide donor, could slowly release nitric oxide in vivo. This study provided a biopharmaceutical basis for further study of nitrofibriate.